Shots:
- Linnaeus will conduct 6 additional P-II cohorts evaluating LNS8801 + Keytruda in several cancer indications while the companies are currently evaluating the combination in patients who had previously responded to PD-1/L1 therapy and also LNS8801 as a monothx in patients unable to tolerate PD-1/L1 therapy due to serious immune-related AEs
- The companies will further evaluate the combination in patients with selected advanced solid tumors, based on promising preliminary safety, PD, and efficacy data
- LNS8801 (PO) is a bioavailable small molecule that is a highly specific & potent agonist of the GPER and ongoing P-I/IIa study demonstrates target engagement, c-Myc oncoprotein depletion, and clinical beneficial for advanced cancer patients
Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post Linnaeus Therapeutics Reports the Expansion of Clinical Collaboration with Merck to Evaluate LNS8801 + Keytruda for the Treatment of Patients with Advanced Cancer first appeared on PharmaShots.
